You are here

Article Text

Article menu
Download PDFPDF
Commentaries
Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?

https://doi.org/10.1136/gutjnl-2016-312492

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All three authors contributed substantially to the writing and editing of this commentary.

    • Funding This work was supported by National Institutes of Health grant DK59427 (GJG) and the Mayo Foundation.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Hepatology
      Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis
      Sebastian Torben Jendrek Daniel Gotthardt Thomas Nitzsche Laila Widmann Tobias Korf Maike Anna Michaels Karl-Heinz Weiss Evaggelia Liaskou Mette Vesterhus Tom Hemming Karlsen Swantje Mindorf Peter Schemmer Florian Bär Bianca Teegen Torsten Schröder Marc Ehlers Christoph Matthias Hammers Lars Komorowski Hendrik Lehnert Klaus Fellermann Stefanie Derer Johannes Roksund Hov Christian Sina
      Gut 2016; 66 137-144 Published Online First: 12 Jul 2016. doi: 10.1136/gutjnl-2016-311739